LRMR

+ Watchlist + Portfolio

Larimar Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.25
52-Week Range: $2.72 – $6.42
Market Cap: $432.15M
P/E (TTM): —
EPS (TTM): -1.96
Dividend Yield: —

Advanced Metrics

Price/Book: 3.41
PEG Ratio: —
Return on Equity: -139.63%
Return on Assets: -70.96%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.70
Debt/Equity: 0.04
Total Debt: $4.96M
Free Cash Flow: $-94.18M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $282.40M

LRMR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$24.25M	$27.67M	$73.28M	$154.22M
Selling, General & Admin	$12.28M	$14.09M	$17.61M	$18.27M
Operating Expenses	$36.53M	$41.76M	$90.89M	$172.50M
Operating Income	-$36.53M	-$41.76M	-$90.89M	-$172.50M
EBITDA	-$36.21M	-$41.45M	-$90.57M	-$172.15M
Pretax Income	-$35.35M	-$36.95M	-$80.60M	-$165.67M
Net Income	-$35.35M	-$36.95M	-$80.60M	-$165.67M
Diluted EPS	-1.37	-0.84	-1.32	-2.27
Diluted Shares	25.76M	43.90M	61.26M	72.95M

LRMR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$26.82M	$26.75M	$33.22M	$85.41M
Receivables	$0.00	$332.00K	$1.05M	$747.00K
Current Assets	$120.74M	$90.17M	$195.30M	$142.02M
Total Assets	$126.41M	$95.94M	$200.22M	$145.84M
Current Liabilities	$10.71M	$9.51M	$24.36M	$64.80M
Total Debt	$5.41M	$5.55M	$5.12M	$4.07M
Total Liabilities	$15.50M	$14.21M	$28.41M	$67.76M
Retained Earnings	-$151.60M	-$188.55M	-$269.16M	-$434.83M
Shareholders' Equity	$110.90M	$81.72M	$171.81M	$78.08M
Working Capital	$110.03M	$80.67M	$170.95M	$77.23M

LRMR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$27.57M	-$33.46M	-$70.76M	-$113.20M
Capital Expenditure	-$100.00K	-$164.00K	-$515.00K	-$91.00K
Free Cash Flow	-$27.67M	-$33.62M	-$71.28M	-$113.29M
Depreciation & Amortisation	$318.00K	$311.00K	$318.00K	$350.00K
Stock-Based Compensation	$6.62M	$7.62M	$8.80M	$7.00M
Investing Cash Flow	-$90.96M	$33.35M	-$85.39M	$100.31M
Financing Cash Flow	$75.26M	$30.00K	$161.88M	$65.09M
Net Change in Cash	-$43.27M	-$76.00K	$5.74M	$52.19M

LRMR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$26.55M	$23.37M	$44.93M	$59.37M	$25.03M
Selling, General & Admin	$4.64M	$4.42M	$4.57M	$4.64M	$6.09M
Operating Expenses	$31.19M	$27.79M	$49.50M	$64.02M	$31.12M
Operating Income	-$31.19M	-$27.79M	-$49.50M	-$64.02M	-$31.12M
EBITDA	-$31.10M	-$27.70M	-$49.41M	-$63.93M	-$31.05M
Pretax Income	-$29.28M	-$26.18M	-$47.71M	-$62.50M	-$29.61M
Net Income	-$29.28M	-$26.18M	-$47.71M	-$62.50M	-$29.61M
Diluted EPS	-0.46	-0.41	-0.61	-0.73	-0.31
Diluted Shares	63.96M	64.03M	78.32M	85.18M	89.81M

LRMR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$21.13M	$20.59M	$90.14M	$85.41M	$177.91M
Receivables	$1.06M	$983.00K	$1.00M	$747.00K	$791.00K
Current Assets	$165.49M	$145.56M	$183.22M	$142.02M	$204.98M
Total Assets	$170.18M	$149.99M	$187.35M	$145.84M	$208.51M
Current Liabilities	$22.13M	$26.65M	$45.12M	$64.80M	$47.76M
Total Debt	$4.87M	$4.61M	$4.35M	$4.07M	$3.78M
Total Liabilities	$25.90M	$30.13M	$48.31M	$67.76M	$50.48M
Retained Earnings	-$298.44M	-$324.62M	-$372.33M	-$434.83M	-$464.44M
Shareholders' Equity	$144.27M	$119.85M	$139.04M	$78.08M	$158.03M
Working Capital	$143.35M	$118.91M	$138.11M	$77.23M	$157.22M

LRMR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$26.54M	-$19.38M	-$28.75M	-$38.53M	-$44.61M
Capital Expenditure	-$49.00K	-$19.00K	-$23.00K	—	—
Free Cash Flow	-$26.59M	-$19.40M	-$28.78M	-$38.53M	-$44.61M
Depreciation & Amortisation	$88.00K	$87.00K	$88.00K	$87.00K	$64.00K
Stock-Based Compensation	$1.83M	$1.83M	$1.78M	$1.56M	$1.98M
Investing Cash Flow	$14.45M	$18.84M	$33.02M	$34.00M	$29.00M
Financing Cash Flow	$0.00	$0.00	$65.29M	-$201.00K	$108.11M
Net Change in Cash	-$12.09M	-$539.00K	$69.55M	-$4.73M	$92.50M

Market Snapshot

About

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for rare diseases, with a primary focus on Friedreich ataxia. The company uses its proprietary platform to develop protein replacement therapies delivered via intrathecal administration. Larimar is advancing its lead candidate through clinical trials targeting mitochondrial diseases and genetic disorders.